Answers are grounded in this paper and cite their sources.
About 85% of all lung cancers are non-small cell lung cancers (NSCLC), which are common, have a high death rate, and are usually diagnosed at an advanced stage. Recent studies have shown that mutations in the TERT promoter in NSCLC may be a noninvasive biomarker, enhance possible treatment approaches, and predict prognosis, especially in inoperable cases. This review comprehensively examines the present state of TERT promoter mutations in NSCLC, highlighting their clinical relevance, treatment approaches, challenges, and key considerations. TERT promoter mutations in NSCLC may offer new perspectives on the molecular pathogenesis of patients. For this reason, summarized TERT promoter mutations in NSCLC and current treatment strategies targeting TERT. Understanding the TERT effect on NSCLC may pave the way for new personalized treatment approaches.
No takes yet. Share an insight, caveat, or question.
Onur Dülger (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: